BioScrip Sees Wider Loss, Misses Estimates - Analyst Blog

By
A A A

In the second quarter of 2013, BioScrip Inc. ( BIOS ) posted adjusted loss per share of 2 cents, flat year over year. However, the result was worse than the Zacks Consensus Estimate of earnings of 3 cents per share.

On a reported basis, BioScrip's net loss from continuing operations of $8.3 million or 13 cents per share was wider than the net loss of $4.3 million or 7 cents per share in the year-ago quarter.

Total revenue rose 22.3% year over year to $190.7 million in the second quarter, trailing well behind the Zacks Consensus Estimate of $206 million. In the second quarter, solid revenue growth was attributable to higher contributions from Infusion Services and Home Health Services business.

The company recorded a robust hike of 40.7% in Infusion Services revenues to $156.2 million on the back of organic volume growth and accretive acquisitions. Revenues from the Home Health Services segment rose 8.1% to $18.2 million, led by volume growth from private duty nursing activity. Lastly, revenues from the PBM Services segment were $16.3 million, down 42% from the prior-year quarter. The decline was due to lower sales volume of discount cards, loss of a client and decrease in funded PBM business.

While the cost of product revenues shot up 36.7% to $102.7 million, the cost of service revenues declined 17.1% to $23 million in the quarter. Gross profit during the quarter rose 22.6% to $65 million with 10 basis points (bps) expansion in gross margin to 34.1%.

Selling, general and administrative (SG&A) expenses increased 27% to $56 million. The surging SG&A resulted in a 50 bps drag in adjusted operating margin in the quarter to 2.8%.

Exiting the quarter, BioScrip had cash balance of $81.6 million compared with $62.1 million at the end of 2012. The company's long-term debt was $225.5 million compared with $226.4 million at the end of 2012.

Outlook

For 2013, BioScrip continues to expect revenues of $830-$865 million, reflecting growth in the range of 25%-30%. The current Zacks Consensus Estimate is pegged at $838 million.

Our Take

BioScrip reported a disappointing quarter missing the Zacks Consensus Estimate on both fronts by a sizeable margin. Further, losses worsened in the quarter. PBM business also continued to decline.

On the bright side, another quarter of strong top-line growth, with most of the upside from the Infusion business, was encouraging. We also look forward to accretion from recent acquisitions.

Currently, the stock carries a Zacks Rank #3 (Hold). While we remain on the sidelines for BioScrip, other stocks such as McKesson Corporation ( MCK ), Herbalife Ltd. ( HLF ) and GNC Holdings Inc. ( GNC ) warrant a look. These stocks carry a Zacks Rank #2 (Buy).



BIOSCRIP INC (BIOS): Free Stock Analysis Report

GNC HOLDINGS (GNC): Free Stock Analysis Report

HERBALIFE LTD (HLF): Free Stock Analysis Report

MCKESSON CORP (MCK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BIOS , GNC , HLF , MCK

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

77,348,481
  • $102.42 ▲ 2.67%
69,166,669
  • $13.19 ▼ 5.79%
60,845,976
  • $16.5915 ▲ 2.04%
43,391,593
  • $40.455 ▼ 6.55%
41,692,147
  • $96.79 ▲ 2.54%
33,553,026
  • $9.275 ▲ 1.26%
31,293,669
  • $31.29 ▲ 5.39%
27,690,754
  • $40.14 ▲ 2.19%
As of 10/21/2014, 03:25 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com